Pharmacy Associations Oppose Rescheduling of Hydrocodone Combination Products

Published Online: Monday, June 16, 2014
Follow Pharmacy_Times:
In a joint pharmacy stakeholder comment letter to the Drug Enforcement Administration, the American Pharmacists Association, National Association of Chain Drug Stores, National Community Pharmacists Association, and other organizations argued that rescheduling hydrocodone combination products from Schedule III to Schedule II will harm legitimate pain patients while doing little to curb abuse.

Rescheduling would mean that patients would need to visit their physicians in order to refill prescriptions for the painkillers, potentially delaying treatment for those with legitimate pain, the letter notes. These patients may have to wait for an appointment or the ability to take time off work to visit a physician, and patients living in rural or medically underserved areas may have to wait even longer to receive treatment. In addition, most patients taking hydrocodone combination products use the medications appropriately, the letter notes.

Rescheduling the medications could also cause inefficiencies in the health care system, the letter adds.

“With approximately 50 million patients taking [hydrocodone combination products], meeting the new demands associated with rescheduling [hydrocodone combination products] may cripple an already overtaxed system,” the letter reads. “Moreover, pharmacies and distributors will have to comply with stricter storage and handling laws for Schedule II controlled substances, and such requirements may cause delays in maintaining an adequate supply of [hydrocodone combination products].”

Related Articles
Purdue Pharma has announced the US commercial launch of its extended-release hydrocodone bitartrate (Hysingla ER), an opioid analgesic indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment in patients for whom alternative treatment options are inadequate.
Pharmacists are getting closer to obtaining provider status, as federal legislation that would enable pharmacists to provide health care services to Medicare patients in underserved communities has been reintroduced in the US Senate and House of Representatives.
The American Pharmacists Association (APhA) applauds today’s introduction of H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act, which will improve patient access to health care through pharmacists and their patient care services.
Bipartisan legislation introduced in the U.S. House of Representatives today would formally designate pharmacists as healthcare providers under Medicare Part B. Supported by the National Association of Chain Drug Stores, the bill would amend The Social Security Act of 1935 to enable pharmacists to provide to Medicare patients in underserved communities services that pharmacists already are providing for other patients under state law.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$